Hypertension

Never-recovered borderline patients had numerically higher rates of hypertension and chronic back pain than ever-recovered patients, but these differences were not statistically significant after Bonf

Effect: null; RRR 0.60 (hypertension); RRR 0.78 (chronic back pain); CI: 95% CI 0.38, 0.96 (hypertension); 95% CI 0.63, 0.96 (chronic back pain)

Never-recovered borderline patients had numerically higher rates of hypertension and chronic back pain than ever-recovered patients, but these differences were not statistically significant after Bonf

Effect: null; RRR 0.60 (hypertension); RRR 0.78 (chronic back pain); CI: 95% CI 0.38, 0.96 (hypertension); 95% CI 0.63, 0.96 (chronic back pain)

Never-recovered borderline patients had numerically higher rates of hypertension and chronic back pain than ever-recovered patients, but these differences were not statistically significant after Bonf

Effect: null; RRR 0.60 (hypertension); RRR 0.78 (chronic back pain); CI: 95% CI 0.38, 0.96 (hypertension); 95% CI 0.63, 0.96 (chronic back pain)

Never-recovered borderline patients had numerically higher rates of hypertension and chronic back pain than ever-recovered patients, but these differences were not statistically significant after Bonf

Effect: null; RRR 0.60 (hypertension); RRR 0.78 (chronic back pain); CI: 95% CI 0.38, 0.96 (hypertension); 95% CI 0.63, 0.96 (chronic back pain)

Never-recovered borderline patients had numerically higher rates of hypertension and chronic back pain than ever-recovered patients, but these differences were not statistically significant after Bonf

Effect: null; RRR 0.60 (hypertension); RRR 0.78 (chronic back pain); CI: 95% CI 0.38, 0.96 (hypertension); 95% CI 0.63, 0.96 (chronic back pain)

Never-recovered borderline patients had numerically higher rates of hypertension and chronic back pain than ever-recovered patients, but these differences were not statistically significant after Bonf

Effect: null; RRR 0.60 (hypertension); RRR 0.78 (chronic back pain); CI: 95% CI 0.38, 0.96 (hypertension); 95% CI 0.63, 0.96 (chronic back pain)

Never-recovered borderline patients had numerically higher rates of hypertension and chronic back pain than ever-recovered patients, but these differences were not statistically significant after Bonf

Effect: null; RRR 0.60 (hypertension); RRR 0.78 (chronic back pain); CI: 95% CI 0.38, 0.96 (hypertension); 95% CI 0.63, 0.96 (chronic back pain)

Never-recovered borderline patients had numerically higher rates of hypertension and chronic back pain than ever-recovered patients, but these differences were not statistically significant after Bonf

Effect: null; RRR 0.60 (hypertension); RRR 0.78 (chronic back pain); CI: 95% CI 0.38, 0.96 (hypertension); 95% CI 0.63, 0.96 (chronic back pain)

Never-recovered borderline patients had numerically higher rates of hypertension and chronic back pain than ever-recovered patients, but these differences were not statistically significant after Bonf

Effect: null; RRR 0.60 (hypertension); RRR 0.78 (chronic back pain); CI: 95% CI 0.38, 0.96 (hypertension); 95% CI 0.63, 0.96 (chronic back pain)

Never-recovered borderline patients had numerically higher rates of hypertension and chronic back pain than ever-recovered patients, but these differences were not statistically significant after Bonf

Effect: null; RRR 0.60 (hypertension); RRR 0.78 (chronic back pain); CI: 95% CI 0.38, 0.96 (hypertension); 95% CI 0.63, 0.96 (chronic back pain)

Never-recovered borderline patients had numerically higher rates of hypertension and chronic back pain than ever-recovered patients, but these differences were not statistically significant after Bonf

Effect: null; RRR 0.60 (hypertension); RRR 0.78 (chronic back pain); CI: 95% CI 0.38, 0.96 (hypertension); 95% CI 0.63, 0.96 (chronic back pain)

Never-recovered borderline patients had numerically higher rates of hypertension and chronic back pain than ever-recovered patients, but these differences were not statistically significant after Bonf

Effect: null; RRR 0.60 (hypertension); RRR 0.78 (chronic back pain); CI: 95% CI 0.38, 0.96 (hypertension); 95% CI 0.63, 0.96 (chronic back pain)

Never-recovered borderline patients had numerically higher rates of hypertension and chronic back pain than ever-recovered patients, but these differences were not statistically significant after Bonf

Effect: null; RRR 0.60 (hypertension); RRR 0.78 (chronic back pain); CI: 95% CI 0.38, 0.96 (hypertension); 95% CI 0.63, 0.96 (chronic back pain)

Never-recovered borderline patients had numerically higher rates of hypertension and chronic back pain than ever-recovered patients, but these differences were not statistically significant after Bonf

Effect: null; RRR 0.60 (hypertension); RRR 0.78 (chronic back pain); CI: 95% CI 0.38, 0.96 (hypertension); 95% CI 0.63, 0.96 (chronic back pain)

Never-recovered borderline patients had numerically higher rates of hypertension and chronic back pain than ever-recovered patients, but these differences were not statistically significant after Bonf

Effect: null; RRR 0.60 (hypertension); RRR 0.78 (chronic back pain); CI: 95% CI 0.38, 0.96 (hypertension); 95% CI 0.63, 0.96 (chronic back pain)

Never-recovered borderline patients had numerically higher rates of hypertension and chronic back pain than ever-recovered patients, but these differences were not statistically significant after Bonf

Effect: null; RRR 0.60 (hypertension); RRR 0.78 (chronic back pain); CI: 95% CI 0.38, 0.96 (hypertension); 95% CI 0.63, 0.96 (chronic back pain)

Never-recovered borderline patients had numerically higher rates of hypertension and chronic back pain than ever-recovered patients, but these differences were not statistically significant after Bonf

Effect: null; RRR 0.60 (hypertension); RRR 0.78 (chronic back pain); CI: 95% CI 0.38, 0.96 (hypertension); 95% CI 0.63, 0.96 (chronic back pain)

Never-recovered borderline patients had numerically higher rates of hypertension and chronic back pain than ever-recovered patients, but these differences were not statistically significant after Bonf

Effect: null; RRR 0.60 (hypertension); RRR 0.78 (chronic back pain); CI: 95% CI 0.38, 0.96 (hypertension); 95% CI 0.63, 0.96 (chronic back pain)

Never-recovered borderline patients had numerically higher rates of hypertension and chronic back pain than ever-recovered patients, but these differences were not statistically significant after Bonf

Effect: null; RRR 0.60 (hypertension); RRR 0.78 (chronic back pain); CI: 95% CI 0.38, 0.96 (hypertension); 95% CI 0.63, 0.96 (chronic back pain)

Never-recovered borderline patients had numerically higher rates of hypertension and chronic back pain than ever-recovered patients, but these differences were not statistically significant after Bonf

Effect: null; RRR 0.60 (hypertension); RRR 0.78 (chronic back pain); CI: 95% CI 0.38, 0.96 (hypertension); 95% CI 0.63, 0.96 (chronic back pain)

Never-recovered borderline patients had numerically higher rates of hypertension and chronic back pain than ever-recovered patients, but these differences were not statistically significant after Bonf

Effect: null; RRR 0.60 (hypertension); RRR 0.78 (chronic back pain); CI: 95% CI 0.38, 0.96 (hypertension); 95% CI 0.63, 0.96 (chronic back pain)

Never-recovered borderline patients had numerically higher rates of hypertension and chronic back pain than ever-recovered patients, but these differences were not statistically significant after Bonf

Effect: null; RRR 0.60 (hypertension); RRR 0.78 (chronic back pain); CI: 95% CI 0.38, 0.96 (hypertension); 95% CI 0.63, 0.96 (chronic back pain)

Never-recovered borderline patients had numerically higher rates of hypertension and chronic back pain than ever-recovered patients, but these differences were not statistically significant after Bonf

Effect: null; RRR 0.60 (hypertension); RRR 0.78 (chronic back pain); CI: 95% CI 0.38, 0.96 (hypertension); 95% CI 0.63, 0.96 (chronic back pain)

Never-recovered borderline patients had numerically higher rates of hypertension and chronic back pain than ever-recovered patients, but these differences were not statistically significant after Bonf

Effect: null; RRR 0.60 (hypertension); RRR 0.78 (chronic back pain); CI: 95% CI 0.38, 0.96 (hypertension); 95% CI 0.63, 0.96 (chronic back pain)

Never-recovered borderline patients had numerically higher rates of hypertension and chronic back pain than ever-recovered patients, but these differences were not statistically significant after Bonf

Effect: null; RRR 0.60 (hypertension); RRR 0.78 (chronic back pain); CI: 95% CI 0.38, 0.96 (hypertension); 95% CI 0.63, 0.96 (chronic back pain)

Never-recovered borderline patients had numerically higher rates of hypertension and chronic back pain than ever-recovered patients, but these differences were not statistically significant after Bonf

Effect: null; RRR 0.60 (hypertension); RRR 0.78 (chronic back pain); CI: 95% CI 0.38, 0.96 (hypertension); 95% CI 0.63, 0.96 (chronic back pain)

Never-recovered borderline patients had numerically higher rates of hypertension and chronic back pain than ever-recovered patients, but these differences were not statistically significant after Bonf

Effect: null; RRR 0.60 (hypertension); RRR 0.78 (chronic back pain); CI: 95% CI 0.38, 0.96 (hypertension); 95% CI 0.63, 0.96 (chronic back pain)

Among controls, women in the highest tertile of serum taurine had 60% lower odds of developing hypertension compared to those in the lowest tertile (OR 0.40, 95% CI 0.17-0.97, p for trend = 0.04). In

Effect: improvement; OR 0.40; CI: 95% CI 0.17-0.97

Among controls, women in the highest tertile of serum taurine had 60% lower odds of developing hypertension compared to those in the lowest tertile (OR 0.40, 95% CI 0.17-0.97, p for trend = 0.04). In

Effect: improvement; OR 0.40; CI: 95% CI 0.17-0.97

Among controls, women in the highest tertile of serum taurine had 60% lower odds of developing hypertension compared to those in the lowest tertile (OR 0.40, 95% CI 0.17-0.97, p for trend = 0.04). In

Effect: improvement; OR 0.40; CI: 95% CI 0.17-0.97

Among controls, women in the highest tertile of serum taurine had 60% lower odds of developing hypertension compared to those in the lowest tertile (OR 0.40, 95% CI 0.17-0.97, p for trend = 0.04). In

Effect: improvement; OR 0.40; CI: 95% CI 0.17-0.97

Among controls, women in the highest tertile of serum taurine had 60% lower odds of developing hypertension compared to those in the lowest tertile (OR 0.40, 95% CI 0.17-0.97, p for trend = 0.04). In

Effect: improvement; OR 0.40; CI: 95% CI 0.17-0.97

Among controls, women in the highest tertile of serum taurine had 60% lower odds of developing hypertension compared to those in the lowest tertile (OR 0.40, 95% CI 0.17-0.97, p for trend = 0.04). In

Effect: improvement; OR 0.40; CI: 95% CI 0.17-0.97

Among controls, women in the highest tertile of serum taurine had 60% lower odds of developing hypertension compared to those in the lowest tertile (OR 0.40, 95% CI 0.17-0.97, p for trend = 0.04). In

Effect: improvement; OR 0.40; CI: 95% CI 0.17-0.97

Among controls, women in the highest tertile of serum taurine had 60% lower odds of developing hypertension compared to those in the lowest tertile (OR 0.40, 95% CI 0.17-0.97, p for trend = 0.04). In

Effect: improvement; OR 0.40; CI: 95% CI 0.17-0.97

Among controls, women in the highest tertile of serum taurine had 60% lower odds of developing hypertension compared to those in the lowest tertile (OR 0.40, 95% CI 0.17-0.97, p for trend = 0.04). In

Effect: improvement; OR 0.40; CI: 95% CI 0.17-0.97

Among controls, women in the highest tertile of serum taurine had 60% lower odds of developing hypertension compared to those in the lowest tertile (OR 0.40, 95% CI 0.17-0.97, p for trend = 0.04). In

Effect: improvement; OR 0.40; CI: 95% CI 0.17-0.97

Among controls, women in the highest tertile of serum taurine had 60% lower odds of developing hypertension compared to those in the lowest tertile (OR 0.40, 95% CI 0.17-0.97, p for trend = 0.04). In

Effect: improvement; OR 0.40; CI: 95% CI 0.17-0.97

Among controls, women in the highest tertile of serum taurine had 60% lower odds of developing hypertension compared to those in the lowest tertile (OR 0.40, 95% CI 0.17-0.97, p for trend = 0.04). In

Effect: improvement; OR 0.40; CI: 95% CI 0.17-0.97

Among controls, women in the highest tertile of serum taurine had 60% lower odds of developing hypertension compared to those in the lowest tertile (OR 0.40, 95% CI 0.17-0.97, p for trend = 0.04). In

Effect: improvement; OR 0.40; CI: 95% CI 0.17-0.97

Among controls, women in the highest tertile of serum taurine had 60% lower odds of developing hypertension compared to those in the lowest tertile (OR 0.40, 95% CI 0.17-0.97, p for trend = 0.04). In

Effect: improvement; OR 0.40; CI: 95% CI 0.17-0.97

Among controls, women in the highest tertile of serum taurine had 60% lower odds of developing hypertension compared to those in the lowest tertile (OR 0.40, 95% CI 0.17-0.97, p for trend = 0.04). In

Effect: improvement; OR 0.40; CI: 95% CI 0.17-0.97

Among controls, women in the highest tertile of serum taurine had 60% lower odds of developing hypertension compared to those in the lowest tertile (OR 0.40, 95% CI 0.17-0.97, p for trend = 0.04). In

Effect: improvement; OR 0.40; CI: 95% CI 0.17-0.97

Among controls, women in the highest tertile of serum taurine had 60% lower odds of developing hypertension compared to those in the lowest tertile (OR 0.40, 95% CI 0.17-0.97, p for trend = 0.04). In

Effect: improvement; OR 0.40; CI: 95% CI 0.17-0.97

Among controls, women in the highest tertile of serum taurine had 60% lower odds of developing hypertension compared to those in the lowest tertile (OR 0.40, 95% CI 0.17-0.97, p for trend = 0.04). In

Effect: improvement; OR 0.40; CI: 95% CI 0.17-0.97

Among controls, women in the highest tertile of serum taurine had 60% lower odds of developing hypertension compared to those in the lowest tertile (OR 0.40, 95% CI 0.17-0.97, p for trend = 0.04). In

Effect: improvement; OR 0.40; CI: 95% CI 0.17-0.97

Among controls, women in the highest tertile of serum taurine had 60% lower odds of developing hypertension compared to those in the lowest tertile (OR 0.40, 95% CI 0.17-0.97, p for trend = 0.04). In

Effect: improvement; OR 0.40; CI: 95% CI 0.17-0.97

Among controls, women in the highest tertile of serum taurine had 60% lower odds of developing hypertension compared to those in the lowest tertile (OR 0.40, 95% CI 0.17-0.97, p for trend = 0.04). In

Effect: improvement; OR 0.40; CI: 95% CI 0.17-0.97

Among controls, women in the highest tertile of serum taurine had 60% lower odds of developing hypertension compared to those in the lowest tertile (OR 0.40, 95% CI 0.17-0.97, p for trend = 0.04). In

Effect: improvement; OR 0.40; CI: 95% CI 0.17-0.97

Among controls, women in the highest tertile of serum taurine had 60% lower odds of developing hypertension compared to those in the lowest tertile (OR 0.40, 95% CI 0.17-0.97, p for trend = 0.04). In

Effect: improvement; OR 0.40; CI: 95% CI 0.17-0.97